Below are the most recent publications written about "Benzoxazines" by people in Profiles.
-
Diphoko T, Gaseitsiwe S, Kasvosve I, Moyo S, Okatch H, Musonda R, Wainberg M, Makhema J, Marlink R, Novitsky V, Essex M. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. AIDS Res Hum Retroviruses. 2018 08; 34(8):667-671.
-
Bisson GP, Molefi M, Bellamy S, Thakur R, Steenhoff A, Tamuhla N, Rantleru T, Tsimako I, Gluckman S, Ravimohan S, Weissman D, Tebas P. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013 Apr; 56(8):1165-73.
-
Reyes BA, Szot P, Sikkema C, Cathel AM, Kirby LG, Van Bockstaele EJ. Stress-induced sensitization of cortical adrenergic receptors following a history of cannabinoid exposure. Exp Neurol. 2012 Aug; 236(2):327-35.
-
Carvalho AF, Van Bockstaele EJ. Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion. Neurosci Lett. 2011 Aug 1; 500(1):82-5.
-
Carvalho AF, Reyes AR, Sterling RC, Unterwald E, Van Bockstaele EJ. Contribution of limbic norepinephrine to cannabinoid-induced aversion. Psychopharmacology (Berl). 2010 Sep; 211(4):479-91.
-
Carvalho AF, Mackie K, Van Bockstaele EJ. Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci. 2010 Jan; 31(2):286-301.
-
Reyes BA, Rosario JC, Piana PM, Van Bockstaele EJ. Cannabinoid modulation of cortical adrenergic receptors and transporters. J Neurosci Res. 2009 Dec; 87(16):3671-8.
-
Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R, Bryson A, Hickling RI. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 Jan; 18(1):108-15.
-
Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, Breidinger SA, Mangin EC, Azrolan N, Greenberg HE, Haazen W, Stone JA, Gottesdiener KM, Wagner JA. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008 Dec; 52(12):4338-43.
-
Fox KM, Sterling RC, Van Bockstaele EJ. Cannabinoids and novelty investigation: influence of age and duration of exposure. Behav Brain Res. 2009 Jan 23; 196(2):248-53.